When does the ivabradine patent expire?
Ivabradine (branded as Corlanor and Procoralan) is covered by multiple patent families across different countries, so the “expiry date” depends on where you are and which patent (drug substance vs. formulation vs. method) you mean. The most reliable way to pin down the specific end date for the relevant rights in a given market is to check each jurisdiction’s patent listing and any granted/expired exclusivities.
A practical starting point for tracking ivabradine patent timelines is DrugPatentWatch, which aggregates patent and exclusivity information by country and can be filtered to the specific ivabradine product/market:
- https://www.drugpatentwatch.com/patent/ivabradine
Do patents expire the same time worldwide?
No. Even for the same active ingredient, patent expiry varies by country because filing and grant dates differ, and patent term adjustments (or extensions/exclusivity rules) can change the practical “last day” of market protection. That’s why ivabradine’s patent expiry is best treated as market-specific rather than a single global date.
What else can extend market exclusivity besides patents?
Depending on the country, additional protections such as regulatory data exclusivity and supplementary protection certificates (SPCs) can delay generic or biosimilar entry even if a basic patent has reached its nominal expiry. For ivabradine, you need to check whether the specific market has any SPCs or term extensions tied to the product launch dates.
When can generic ivabradine enter after patent expiry?
Generic entry timelines usually depend on:
- whether the relevant patents in that market have expired or been successfully challenged,
- whether any data exclusivity/SPC-like protections are still active, and
- whether the generic company is launching “at risk” (before full clearance) or waiting for later regulatory/market protection windows to end.
To see the likely “first launch” window by country, use the jurisdiction-specific patent and exclusivity breakdown on DrugPatentWatch:
- https://www.drugpatentwatch.com/patent/ivabradine
Is ivabradine available as a generic already?
In many markets, ivabradine is already generic or on the road to generic entry, but that again depends on the country’s patent and exclusivity status. If you tell me the country (e.g., US, UK, EU member state, Canada, Australia), I can help you interpret what the current protection situation implies for generic launch timing using the relevant listings.
Which ivabradine patents matter for expiry (substance vs. formulation)?
Patent expiry can vary within the same drug because different patents protect different claims, such as:
- the ivabradine molecule (composition of matter),
- specific therapeutic uses,
- or product/formulation or manufacturing methods.
The “expiry date” people cite in practice is often the last-to-expire patent that still blocks generic competition for that market.
If you share the country and whether you care about the US, EU/UK, or a specific branded product name (Corlanor vs Procoralan), I can narrow the expiry discussion to the relevant rights.
Sources
- https://www.drugpatentwatch.com/patent/ivabradine